Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pliant Therapeutics (PLRX) Cash & Equivalents (2019 - 2026)

Pliant Therapeutics has reported Cash & Equivalents over the past 8 years, most recently at $22.2 million for Q1 2026.

  • Quarterly Cash & Equivalents fell 75.86% to $22.2 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $22.2 million through Mar 2026, down 75.86% year-over-year, with the annual reading at $45.4 million for FY2025, 36.16% down from the prior year.
  • Cash & Equivalents was $22.2 million for Q1 2026 at Pliant Therapeutics, down from $45.4 million in the prior quarter.
  • Over five years, Cash & Equivalents peaked at $114.3 million in Q1 2024 and troughed at $22.2 million in Q1 2026.
  • The 5-year median for Cash & Equivalents is $63.2 million (2023), against an average of $64.7 million.
  • Year-over-year, Cash & Equivalents skyrocketed 215.03% in 2023 and then tumbled 75.86% in 2026.
  • A 5-year view of Cash & Equivalents shows it stood at $33.7 million in 2022, then surged by 87.72% to $63.2 million in 2023, then grew by 12.58% to $71.2 million in 2024, then tumbled by 36.16% to $45.4 million in 2025, then tumbled by 51.17% to $22.2 million in 2026.
  • Per Business Quant, the three most recent readings for PLRX's Cash & Equivalents are $22.2 million (Q1 2026), $45.4 million (Q4 2025), and $93.7 million (Q3 2025).